{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tuberculosis%2C+Pulmonary",
    "query": {
      "condition": "Tuberculosis, Pulmonary"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tuberculosis%2C+Pulmonary&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:49:56.385Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001033",
      "title": "The Treatment of Tuberculosis in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Ethambutol hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 650,
      "start_date": null,
      "completion_date": "1997-07",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001033"
    },
    {
      "nct_id": "NCT04826809",
      "title": "New Reusable Mask Design With Superior Filtration and Fit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Covid19",
        "Tuberculosis",
        "Respiratory Viral Infection"
      ],
      "interventions": [
        {
          "name": "N95 mask",
          "type": "DEVICE"
        },
        {
          "name": "Nordell single E-100 layer mask",
          "type": "DEVICE"
        },
        {
          "name": "Nordell double E-100 layer mask",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2021-04-09",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 1,
      "location_summary": "Mankato, Minnesota",
      "locations": [
        {
          "city": "Mankato",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04826809"
    },
    {
      "nct_id": "NCT00023335",
      "title": "TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "1995-04",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2005-09-05",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023335"
    },
    {
      "nct_id": "NCT02410772",
      "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifapentine",
          "type": "DRUG"
        },
        {
          "name": "rifapentine and moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410772"
    },
    {
      "nct_id": "NCT04865536",
      "title": "Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBI-223 1800 mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 2400mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-02-03",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04865536"
    },
    {
      "nct_id": "NCT00685360",
      "title": "A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis, Pulmonary",
        "Tuberculosis, Multidrug Resistant",
        "Extensively Drug-Resistant Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Delamanid",
          "type": "DRUG"
        },
        {
          "name": "Optimized Background Regimen (OBR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 481,
      "start_date": "2008-05-08",
      "completion_date": "2010-06-11",
      "has_results": true,
      "last_update_posted_date": "2021-12-01",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685360"
    },
    {
      "nct_id": "NCT01162486",
      "title": "Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "Rifampin & midazolam",
          "type": "DRUG"
        },
        {
          "name": "rifapentine and midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2010-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01162486"
    },
    {
      "nct_id": "NCT00694629",
      "title": "TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifampin",
          "type": "DRUG"
        },
        {
          "name": "rifapentine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2008-12",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694629"
    },
    {
      "nct_id": "NCT04884308",
      "title": "Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Bronchiectasis Adult",
        "Non-Tuberculous Mycobacteria"
      ],
      "interventions": [
        {
          "name": "BCG TICE Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-28",
      "completion_date": "2023-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04884308"
    },
    {
      "nct_id": "NCT04048018",
      "title": "Performance Evaluation of the VIDAS TB-IGRA Assay.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Active Tuberculosis",
        "Latent Tuberculosis Infection",
        "Non-Tuberculous Mycobacterial (NTM) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Blood draw and IGRA test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "BioMérieux",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 2401,
      "start_date": "2019-12-05",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-05-22T04:49:56.385Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • San Diego, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04048018"
    }
  ]
}